miRNAs: mediators of ErbB family targeted therapy resistance

• Type: Another Publication in an International Scientific Journal
• Date: 2016

Authors

Adem, BF (Author) Other; Alves Bastos, NRA (Author) Other; Dias, F (Author) Other; Teixeira, AL (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Pharmacogenomics

Vol. 17

Pages: 1175-1187

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-00K-NNX

DOI: 10.2217/pgs-2016-0038

Abstract (EN): The ErbB/HER tyrosine kinase receptors family plays a key regulatory role in different cellular processes by activating several signaling pathways. In different tumor types, mutations or overexpression of the ErbB family members are a common feature, which led to the development of targeted therapies against this receptors. Although with this kind of treatment we are heading to a more personalized medicine, the development of acquired resistance is still an issue, therefore, several studies focused on discovering the mechanisms behind it. More recently, miRNAs have been described as important mediators of acquired resistance, specifically, acquired resistance to ErbB family targeted therapies. Ultimately, miRNA-based therapeutics using exosomes as a drug delivery model can revolutionize today's approach of cancer treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13